Effects of mitogen-activated protein kinase pathway and co-activator CREP-binding protein on peroxisome proliferator-activated receptor-γ-mediated transcription suppression of angiotensin II type 1 receptor gene

Hypertension Research

Volumn 26, Issue 8, 2003, Pages 623-628

  Sugawara, Akira ^a   Takeuchi, Kazuhisa ^a   Uruno, Akira ^a   Kudo, Masataka ^a   Sato, Kazunori ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Mitogen activated protein kinase kinase; Nuclear hormone receptor; Prostaglandin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN 2 RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOSINE; GUANINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P300; SYNAPTOPHYSIN;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CELLS, CULTURED; CREB-BINDING PROTEIN; ENZYME INHIBITORS; FLAVONOIDS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH, VASCULAR; NUCLEAR PROTEINS; PHOSPHORYLATION; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUPPRESSION, GENETIC; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0042327752     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.623     Document Type: Article

References (34)

1. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW: Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997; 29: 366-373.
2. Berk BC: Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol 1999; 10 (Suppl 11): S62-S68.
3. Murphy TJ, Takeuchi K, Alexander RW: Molecular biology of vascular type-1 angiotensin II receptor. Am J Hypertens 1992; 5: 236S-242S.
4. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG: Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281: H2337-H2365.
5. Timmermans PB: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147-153.
6. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
7. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-812.
8. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
9. Shiomi M, Ito T, Tsukada T, Tsujita Y, Horikoshi H: Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 142: 345-353.
10. Shinohara E, Kihara S, Ouchi N, et al: Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998; 136: 275-279.
11. Sugawara A, Takeuchi K, Uruno A, et al: Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res 2001; 24: 229-233.
12. Sugawara A, Takeuchi K, Uruno A, et al: Transcriptional suppression of type-1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-3134.
13. Reginato MJ, Krakow SL, Bailey ST, Lazar MA: Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 1998; 273: 1855-1858.
14. Chen S, Johnson BA, Li Y, et al: Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function. J Biol Chem 2000; 275: 3733-3736.
15. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE: Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 73-82.
16. Kawahara K, Watanabe S, Ohshima T, et al: Hypernuclear acetylation in atherosclerotic lesions and activated vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 266: 417-424.
17. Nakajima T, Fukamizu A, Takahashi J, et al: The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell 1996; 86: 465-474.
18. Sugawara A, Sanno N, Takahashi N, Osamura RY, Abe K: Retinoid X receptors in the kidney: their protein expression and functional significance. Endocrinology 1997; 138: 3175-3180.
19. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
20. Wang XZ, Ron D: Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 1996; 272: 1347-1349.
21. Sandberg K, Ji H, Catt KJ: Regulation of angiotensin II receptors in rat brain during dietary sodium changes. Hypertension 1994; 23 (Suppl 1): I137-I141.
22. Takahashi N, Takeuchi K, Sugawara A, et al: Structure and transcriptional function of the 5′-flanking region of rat thromboxane receptor gene. Biochem Biophys Res Commun 1998; 244: 489-493.
23. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
24. Sugawara A, Yen PM, Qi Y, Lechan RM, Chin WW: Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 1995; 136: 1766-1774.
25. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE: Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 1997; 417: 283-286.
26. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE: Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997; 29: 334-339.
27. Goetze S, Xi XP, Kawano Y, et al: TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999; 33: 183-189.
28. Graf K, Xi XP, Hsueh WA, Law RE: Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 1997; 400: 119-121.
29. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE: Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999; 452: 277-282.
30. Bannister AJ, Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 1996; 384: 641-643.
31. Ait-Si-Ali S, Carlisi D, Ramirez S, et al: Phosphorylation by p44 MAP kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro. Biochem Biophys Res Commun 1999; 262: 157-162.
32. Tedgui A, Mallat Z: Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-887.
33. Suzuki T, Kimura A, Nagai R, Horikoshi M: Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 2000; 5: 29-41.
34. Kundu TK, Palhan VB, Wang Z, An W, Cole PA, Roeder RG: Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell 2000; 6: 551-561.